The investment will accelerate the delivery of tests addressing kidney function and cardiac risk expected to gain U.S. Food and Drug Administration 510(k) approval early next year, according to the announcement.
WHY IT MATTERS
Using algorithms to analyze multiple biomarkers to measure disease…
From: www.healthcareitnews.com – Read more
The True Cost of Focusing on Cost Instead of Cost-Effectiveness
When payors consider only the cost of the medication and not the cost and risk to the patient, doctor, and healthcare system, the irony is
